Biomanufacturing: Advancing life sciences industry in Canada

From: Innovation, Science and Economic Development Canada

Biomanufacturing in Canada

Ensuring access to critical vaccines, therapeutics and other health products is a priority for the Government of Canada. At the outset of the COVID-19 pandemic, the Government of Canada took early and decisive action to strengthen Canada's biomanufacturing capacity to protect Canadians. We continue to invest in domestic biomanufacturing capabilities and secure medical countermeasures.

Explore the 5-pillar strategy to strengthen the biomanufacturing and life sciences sector

Learn about Canada’s first plant-based manufacturing facility to both develop and manufacture vaccines and therapeutics

Advancing the life sciences industry

Since March 2020, the government has taken a multifaceted approach including over $1 billion in advance purchase agreements to secure a domestic supply of up to 429 million doses of promising COVID-19 vaccines. The Government of Canada has also committed $792 million through the Strategic Innovation Fund (SIF), to support research and development, clinical trials, and the manufacturing of vaccines and therapeutic drugs to fight COVID-19.

Innovation, Science, and Economic Development Canada – in partnership with Health Canada, the Public Health Agency of Canada, and partner departments and agencies – is actively engaging with stakeholders. This engagement is to explore ways that the Government of Canada can support future pandemic preparedness, including through vaccine and therapeutic manufacturing in Canada.

Related links:

• Backgrounder – Government of Canada investments in biomanufacturing, development of COVID-19 vaccines and therapeutics, and research
• Major investments in domestic firms to rebuild Canada's biomanufacturing sector
• Federal, Provincial and Territorial Ministers discuss rebuilding biomanufacturing in Canada
• New support to produce COVID-19 vaccines and treatments in Canada

Contact